about
sameAs
Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancerSubtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancerH3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERα ligand dependencyARID1A mutations in endometriosis-associated ovarian carcinomasAn Immunohistochemical Algorithm for Ovarian Carcinoma Typing.RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancerHaplotype analysis suggest common founders in carriers of the recurrent BRCA2mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer familiesMolecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancerHuman TDE1, a TDE1/TMS family member, inhibits apoptosis in vitro and stimulates in vivo tumorigenesisStimulation of Wnt/ß-catenin pathway in human CD8+ T lymphocytes from blood and lung tumors leads to a shared young/memory phenotypePotential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneA framework for biobank sustainability.Proteomic profiling of a mouse model for ovarian granulosa cell tumor identifies VCP as a highly sensitive serum tumor marker in several human cancers.Proteome profiling of human epithelial ovarian cancer cell line TOV-112D.Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroidsHaplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.Characterization of three new serous epithelial ovarian cancer cell lines.Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines.Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.Role of Pirh2 in mediating the regulation of p53 and c-Myc.Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.Necdin, a p53-target gene, is an inhibitor of p53-mediated growth arrest.An essential role for Ran GTPase in epithelial ovarian cancer cell survival.BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosisVGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancerDerivation and characterization of matched cell lines from primary and recurrent serous ovarian cancerThe genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.Positional mapping and candidate gene analysis of the mouse Ccs3 locus that regulates differential susceptibility to carcinogen-induced colorectal cancer.Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2.A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastasesGermline TP53 mutational spectrum in French Canadians with breast cancer.Signature of a silent killer: expression profiling in epithelial ovarian cancer.Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder populationChemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors.
P50
Q21136183-0B3A28CC-720A-456B-8D1D-01EDC6E98FFBQ24307419-E215C7CF-9964-4C1B-BAB9-14E9B60C33B2Q24322697-2B37257B-598B-405E-ABE0-A0FD9632AF89Q24610484-79BA397A-091A-4B98-A774-6F7314A614C8Q27313766-F95A71C2-1207-4464-83D4-437EC1996F10Q27316858-BEFFDC01-1D59-4C45-A2E7-F11B52FE6C9BQ27496673-B4016EFC-E476-43BB-A69C-9039D786C702Q28247934-86772EFE-0484-47ED-A5D7-63FDCF1F2F8EQ28302832-BCA21E91-E202-4350-ABF1-0D56968DBFACQ28481655-E178CBD5-141E-4F1C-97EE-9D8E295FA30BQ28546630-BDF3CBED-6426-42C3-912B-7523C5886562Q28553703-90D4EFCB-C968-4C3D-881E-C6BAEC60DA50Q28656236-34D9223B-BD5E-4D84-BCEE-5D1D4F8E6AB3Q30425624-0E681220-6A31-4E40-9776-50DA6E75740BQ33228818-B7AC4FD6-D906-48F6-BECF-877405FCDFFFQ33321330-3AB86E96-B4AC-4881-B476-D1FFB935960EQ33327591-082B9661-F95B-40AB-922F-2AEDD6935C2EQ33338286-454CCCD3-1904-4A35-B014-4B24E47BA52CQ33358552-CA046E25-9DDA-4BB1-BA76-6365386460DAQ33387074-1CD2C55E-2540-4FC5-806A-19807E9F4835Q34085616-56B9121E-AEC7-4C26-8C8D-019969FDBDBFQ34097804-AF2B433A-6A2A-41CA-94BF-7A17B75AB901Q34166515-DE9AB655-462E-4B01-BC0B-CE1C51C47A21Q34243626-1987058F-C362-4B4A-B15B-C85AF31316A9Q34299655-EAC6F328-6593-45F1-9C50-C11B52D1D71AQ34328133-6DBB6C0B-3583-4ABA-8212-CFCB183C95CAQ34397197-3DF66208-2A5C-4508-9F2F-54FB35B51EC6Q34429176-1932AC98-2307-4258-A8B2-8F663EE43FFDQ34542998-C955556E-A0FA-4C15-B276-A132CC18487DQ34629951-7469E008-1A65-40A2-AE07-B675A8CBEE66Q35003102-82BB9D21-4716-4691-B77A-56CD558204DBQ35161567-D4C38CC6-7E42-45FF-AF1B-7C073B99EDC5Q35223166-3A39C7AD-2127-4F04-94DE-F5C2D8B167F3Q35237915-E4046689-4851-4869-865B-110B74AA406BQ35274995-1AAE7A00-AE32-4F56-A61F-AB455CF9ACC4Q35549911-C4720CA6-1A81-45BD-A5FE-B359AD2ED313Q35618321-6E079E28-4847-4F02-886E-A82FDADB8F35Q35680306-622B933D-7547-4A3B-9E9A-7EA585E48E77Q35758939-FA3664CB-3C4D-45E6-933D-7E272ABBC14FQ35768691-5BD61DD5-51C3-495D-A20B-3B54417E0B73
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anne-Marie Mes-Masson
@ast
Anne-Marie Mes-Masson
@en
Anne-Marie Mes-Masson
@es
Anne-Marie Mes-Masson
@fr
Anne-Marie Mes-Masson
@nl
Anne-Marie Mes-Masson
@sl
type
label
Anne-Marie Mes-Masson
@ast
Anne-Marie Mes-Masson
@en
Anne-Marie Mes-Masson
@es
Anne-Marie Mes-Masson
@fr
Anne-Marie Mes-Masson
@nl
Anne-Marie Mes-Masson
@sl
prefLabel
Anne-Marie Mes-Masson
@ast
Anne-Marie Mes-Masson
@en
Anne-Marie Mes-Masson
@es
Anne-Marie Mes-Masson
@fr
Anne-Marie Mes-Masson
@nl
Anne-Marie Mes-Masson
@sl
P106
P21
P31
P496
0000-0002-6498-266X